Agenus to Participate in Brain Cancer Vaccine and Immunotherapy Discussion on September 23rd Webcast

  Agenus to Participate in Brain Cancer Vaccine and Immunotherapy Discussion
  on September 23rd Webcast

Business Wire

LEXINGTON, Mass. -- September 18, 2013

Agenus Inc. (NASDAQ: AGEN) today announced that Dr. Garo Armen, chairman and
CEO of Agenus, will participate in a webcast, titled “Glioblastoma – Brain
Cancer: The Next Generation of Therapies,” being sponsored by ProActive
Capital Group on Monday, September 23, 2013 at 12 noon ET. The webcast will
feature two medical experts in the field of glioblastoma multiforme (GBM) in a
moderated discussion of immunological approaches for the treatment of brain

  *Andrew T. Parsa, MD, PhD, Michael J. Marchese Professor and Chair,
    Department of Neurological Surgery at Northwestern University School of
  *John A. Boockvar, MD, Professor of Neurological Surgery and Co-director of
    the Brain and Spinal Tumor Program at the Weill Cornell Brain and Spine

The discussion will be moderated by the biotechnology team at Maxim Group, led
by Jason Kolbert.

Webcast Information

To access the live audio webcast, please log on through a link located on
Agenus’ website and use passcode 40290515. A replay
of the webcast will be available approximately one hour after the conclusion
of the live event.

About Glioblastoma Multiforme (GBM)

The incidence rates of primary malignant brain and central nervous system
cancers have increased over the last three decades.^1 The American Cancer
Society estimates that more than 23,000 malignant tumors of the brain or
spinal cord will be diagnosed during 2013 in the US, and that more than 14,000
people will die from these tumors. ^ 2 GBM is the most common primary
malignant brain tumor and accounts for the majority of diagnoses. It has been
associated with a particularly poor prognosis, with survival rates at one and
five years equaling 33.7% and 4.5%, respectively.^3 The current standard of
care for patients with newly diagnosed GBM is surgical resection followed by
fractionated external beam radiotherapy and systemic temozolomide^4 resulting
in a median OS of 14.6 months^5 based on data from a randomized Phase 3 trial.
Although this treatment can prolong survival, it is not curative and the vast
majority of patients with GBM experience recurrent disease, with a median time
to recurrence of seven months.^6 Currently, there is no standard treatment for
patients with recurrent GBM, although additional surgery, chemotherapy (i.e.,
CCNU, temozolomide), bevacizumab, and radiotherapy are used.

About the Prophage Series (HSPPC-96) Cancer Vaccines

The Prophage Series G vaccines are currently being studied in two different
settings of GBM: newly diagnosed and recurrent disease. Prophage Series cancer
vaccines are autologous therapies derived from cells extracted from the
patient’s tumor. As a result, Prophage Series vaccines contain a precise
antigenic ‘fingerprint’ of a patient’s particular cancer and are designed to
reprogram the body’s immune system to target only cells bearing this
fingerprint, reducing the risk that powerful anti-cancer agents will target
healthy tissue and cause debilitating side effects often associated with
chemotherapy and radiation therapy.

About Agenus

Agenus Inc. is a biotechnology company working to develop treatments for
cancers and infectious diseases. The company is focused on immunotherapeutic
products based on strong platform technologies with multiple product
candidates advancing through the clinic, including several product candidates
that have advanced into late-stage clinical trials through corporate partners.
Between Agenus and its partners, 23 programs are in clinical development. For
more information, please visit, or connect with the company
on Facebook, LinkedIn, Twitter and Google+.

Forward-Looking Statement

This press release contains forward-looking statements, including statements
regarding up-coming presentations and the potential application of the
Company’s technologies and product candidates in the prevention and treatment
of diseases. These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially. These
risks and uncertainties include, among others, the factors described under the
Risk Factors section of our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission for the period ended June 30, 2013. Agenus
cautions investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only as of the
date of this document, and Agenus undertakes no obligation to update or revise
the statements. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement. Agenus’ business is subject to
substantial risks and uncertainties, including those identified above. When
evaluating Agenus’ business and securities, investors should give careful
consideration to these risks and uncertainties.


1. Maher EA, McKee AC. In: Atlas of diagnostic oncology. 3. Skarin AT,
Canellos GP, editor. London: Elsevier Science; 2003. Neoplasms of the central
nervous system; pp. 5–10.


3. Central Brain Tumor Registry of the United States (CBTRUS) 2010 CBTRUS
statistical report: primary brain and central nervous system tumors diagnosed
in the United States in 2004-2006.

4. National Comprehensive Cancer Network clinical practice guidelines in
oncology-central nervous system cancers. v.1.2010.

5. Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med, 2005. 352(10): p. 987-96.

6. Wen PY, DeAngelis LM. Chemotherapy for low-grade gliomas: emerging
consensus on its benefits. Neurology. 2007;68(21):1762–1763. doi:


Media and Investor Contact:
Agenus Inc.
Jonae R. Barnes, 617-818-2985
Vice President Investor Relations and Corporate Communications
Press spacebar to pause and continue. Press esc to stop.